Clinical Advances in Nasopharyngeal Carcinoma : Episode 4
Opinion
Video
Value of PD-L1 Biomarker in NPC
Author(s):
A medical oncologist discusses the value of PD-L1 as a biomarker in the treatment of patients with nasopharyngeal carcinoma.
EP: 1.Differentiating Nasopharyngeal Carcinoma from Other Head & Neck Cancers: The Value of a Multidisciplinary Approach
EP: 2.Current Guidelines for Managing Nasopharyngeal Carcinoma
EP: 3.Overview of the JUPITER and POLARIS-2 Trials
Now Viewing
EP: 4.Value of PD-L1 Biomarker in NPC
EP: 5.Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab
EP: 6.Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors
EP: 7.Strategies to Mitigate Adverse Events in Nasopharyngeal Carcinoma Treatment
EP: 8.Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma
EP: 9.Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects
EP: 10.Clinical Scenario: Locally Recurrent NPC
EP: 11.Clinical Scenario: Metastatic EBV-Positive NPC
Video content above is prompted by the following:
- What is the value of PD-L1 as a biomarker in the treatment of patients with nasopharyngeal carcinoma?
Related Videos
Related Content
